>
Fusen Pharmaceutical Co logo

1652 - Fusen Pharmaceutical Co Share Price

HK$2.83 0.1  3.7%

Last Trade - 9:08am

Sector
Healthcare
Size
Small Cap
Market Cap £195.1m
Enterprise Value £182.3m
Revenue £53.9m
Position in Universe 2318th / 6114
Bullish
Bearish
Unlock 1652 Revenue
Momentum
Relative Strength (%)
1m -20.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -61.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
368.6 442 452.6 462.1 407.4 486.9 +5.7%
+111.8 +1.8 -9.1 -54.6 +67.8
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, FusenPharmaceutical Co Ltd revenues increased 20% to RMB486.9M.Net income increased 31% to RMB70.1M. Revenues reflectShuanghuanglian Oral Solutions segment increase of 40% toRMB295.2M, Others segment increase of 11% to RMB145.6M. Netincome benefited from Share of profit of a joint ventureincrease from RMB4.5M to RMB24.3M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

1652 Revenue Unlock 1652 Revenue

Net Income

1652 Net Income Unlock 1652 Revenue

Normalised EPS

1652 Normalised EPS Unlock 1652 Revenue

PE Ratio Range

1652 PE Ratio Range Unlock 1652 Revenue

Dividend Yield Range

1652 Dividend Yield Range Unlock 1652 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
1652 EPS Forecasts Unlock 1652 Revenue
Profile Summary

Fusen Pharmaceutical Co Ltd is a China-based company principally engaged in the provision of Shuanghuanglian series cold medicines. The Company is mainly engaged in research, development, production and sales of Chinese patent drugs and western medicine products for the treatment of cold and fever, cardiovascular diseases and anemia. The Company's main products include small volume injections, oral liquids, tablets, capsules and granules. The Company distributes its products mainly in domestic market.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated January 18, 2013
Public Since July 11, 2018
No. of Shareholders: n/a
No. of Employees: 1,248
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 774,012,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
1652 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 1652
Upcoming Events for 1652
Wednesday 30th June, 2021 Estimate
Fusen Pharmaceutical Company Ltd Annual Shareholders Meeting
Frequently Asked Questions for Fusen Pharmaceutical Co
What is the Fusen Pharmaceutical Co share price?

As of 9:08am, shares in Fusen Pharmaceutical Co are trading at HK$2.83, giving the company a market capitalisation of £195.1m. This share price information is delayed by 15 minutes.

How has the Fusen Pharmaceutical Co share price performed this year?

Shares in Fusen Pharmaceutical Co are currently trading at HK$2.83 and the price has moved by -18.51% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Fusen Pharmaceutical Co price has moved by -40.96% over the past year.

What are the analyst and broker recommendations for Fusen Pharmaceutical Co?

There are no analysts currently covering Fusen Pharmaceutical Co.

When will Fusen Pharmaceutical Co next release its financial results?

Fusen Pharmaceutical Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Fusen Pharmaceutical Co dividend yield?

The Fusen Pharmaceutical Co dividend yield is 0.39% based on the trailing twelve month period.

Does Fusen Pharmaceutical Co pay a dividend?

Last year, Fusen Pharmaceutical Co paid a total dividend of 0.01, and it currently has a trailing dividend yield of 0.39%. Looking ahead, Fusen Pharmaceutical Co has not announced an ex-dividend date yet and the next dividend pay date is 2021-07-16.

When does Fusen Pharmaceutical Co next pay dividends?

Fusen Pharmaceutical Co has yet to annouce their ex-dividend date and the next dividend pay date is 2021-07-16. The historic dividend yield on Fusen Pharmaceutical Co shares is currently 0.39%.

How do I buy Fusen Pharmaceutical Co shares?

To buy shares in Fusen Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Fusen Pharmaceutical Co?

Shares in Fusen Pharmaceutical Co are currently trading at HK$2.83, giving the company a market capitalisation of £195.1m.

Where are Fusen Pharmaceutical Co shares listed? Where are Fusen Pharmaceutical Co shares listed?

Here are the trading details for Fusen Pharmaceutical Co:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 1652
What kind of share is Fusen Pharmaceutical Co?

Based on an overall assessment of its quality, value and momentum, Fusen Pharmaceutical Co is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Fusen Pharmaceutical Co share price forecast 2021?

We were not able to load any forecast data for Fusen Pharmaceutical Co.

How can I tell whether the Fusen Pharmaceutical Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fusen Pharmaceutical Co. Over the past six months, the relative strength of its shares against the market has been -46.11%. At the current price of HK$2.83, shares in Fusen Pharmaceutical Co are trading at -37.98% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Fusen Pharmaceutical Co PE Ratio?

The Fusen Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 20.4. The shares are currently trading at HK$2.83.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Fusen Pharmaceutical Co?

Fusen Pharmaceutical Co's management team is headed by:

Changcheng Cao - CHM
Taisheng Hou - EDR
Yongsheng Chi - EDR
Qingfen Meng - EDR
Dudu Cao - CEO
Jianhang Wang - NED
Wing Chun Sze - NID
Kwok Tung Lee - NID
Zhen Li - CFO
Jiancheng Fu - VPR
Kit Wa To - NID
Zhiming Cao - EDR
Tik Man Wong - SEC
Who are the major shareholders of Fusen Pharmaceutical Co?

Here are the top five shareholders of Fusen Pharmaceutical Co based on the size of their shareholding:

Rayford Global Ltd Corporation
Percentage owned: 23.28% (180.2m shares)
Cao (Changcheng) Individual Investor
Percentage owned: 23.28% (180.2m shares)
Cao (Zhiming) Individual Investor
Percentage owned: 16.39% (126.8m shares)
Lam (Yiu Por) Individual Investor
Percentage owned: 5.16% (40.0m shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 0.03% (198k shares)
Similar to 1652
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.